Welcome to our dedicated page for MiNK Therapeutics SEC filings (Ticker: INKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MiNK Therapeutics, Inc. filings document a clinical-stage biopharmaceutical company focused on allogeneic iNKT cell therapies, including formal disclosures about agenT-797, program updates, operating results and financing activity. Current reports have covered quarterly and annual financial results, clinical and publication-related updates, potential strategic discussions, and an at-the-market common stock sales agreement registered under a shelf registration statement.
The company’s proxy and governance filings disclose annual meeting matters, director elections, auditor ratification, board appointments, officer designations and compensation-related items. Other filings describe its Nasdaq-listed common stock, equity incentive plan activity, intercompany services arrangements with Agenus for finance functions, and risk-sensitive updates related to clinical development, capital needs and public-company governance.
MiNK Therapeutics, Inc. reported a Q2 2026 net loss of $3.1 million, narrower than $4.2 million a year earlier, as research and development expense was $1.9 million and general and administrative expense declined to $1.3 million. For the first six months, net loss was $5.9 million versus $7.0 million in 2025.
Cash and cash equivalents were $8.8 million at June 30, 2026, after using $3.8 million in operating cash and repaying a $5.0 million related-party convertible note in January 2026. The company raised $4.4 million by selling 313,478 shares under its at-the-market equity program, with $30.6 million of capacity remaining.
Accumulated deficit reached $162.5 million, and MiNK reported stockholders’ deficit of $14.0 million alongside $16.1 million due to related parties that Agenus has agreed not to call for repayment for the foreseeable future. Management states that, despite expected funding, substantial doubt exists about the company’s ability to continue as a going concern for one year after the report date.
MiNK Therapeutics, Inc. reported second quarter 2026 results and clinical progress for its lead iNKT cell therapy, agenT-797. Cash and cash equivalents were $8.8 million as of June 30, 2026. Net loss for the quarter was $3.1 million, or $0.62 per share, compared with $4.2 million, or $1.06 per share, in the second quarter of 2025. For the first six months of 2026, net loss was $5.9 million, or $1.20 per share, versus $7.0 million, or $1.76 per share, a decrease attributed to expense discipline.
Clinically, MiNK reported initial Day 28 observations from its randomized Phase 2 trial C-1300-02 of agenT-797 in acute lung injury/ARDS, with treated patients alive at Day 28, improved oxygenation, infection control, and no major serious adverse events attributed to agenT-797 in these initial patients. The company also launched a paid, per-patient, physician-initiated named-patient access program for agenT-797 in Brazil, which may generate non-promotional revenue while expanding access under regulatory oversight.
MiNK Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 17, 2026. A total of 3,277,906 shares of common stock were present in person or by proxy, representing 65.79% of shares outstanding and establishing a quorum.
Stockholders elected Garo Armen, Barbara Ryan and John Holcomb as Class II directors for three-year terms ending at the 2029 annual meeting. Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
MiNK Therapeutics director Barbara Ryan reported selling a total of 1,500 shares of Common Stock in open-market transactions. The sales on June 4, 2026 were executed at prices of $12.7995 for 1,000 shares and $12.6835 for 500 shares. Following these transactions, she directly holds 21,969 shares of MiNK Therapeutics common stock. According to the filing, the shares sold had been received as compensation for services as a member of the company’s Board of Directors.
Holcomb John Bradley reported acquisition or exercise transactions in this Form 4 filing.
MiNK Therapeutics, Inc. director John Bradley Holcomb reported two stock-based compensation grants. On June 1, 2026, he received 1,091 shares of Common Stock as restricted stock units (RSUs) valued at $12.38 per share in lieu of cash board and committee retainers.
On March 2, 2026, he received an additional 1,239 RSU-based shares at $10.90 per share for Q1 2026 service. The filing notes these Q1 RSUs were not filed earlier due to an administrative error. After these awards, he directly holds 3,458 shares of MiNK Therapeutics common stock. The RSUs vest one month after each grant date, reflecting routine non-cash director compensation rather than open-market purchases.
MiNK Therapeutics director Barbara Ryan reported stock-based board compensation rather than open-market trades. On June 1, 2026, she received 1,434 shares of common stock valued at $12.38 per share as a grant in lieu of cash retainers, bringing her direct holdings to 23,469 shares.
The filing also reports a prior grant on March 2, 2026 of 1,629 shares at $10.90 per share, likewise received instead of cash board and committee fees. Footnotes explain these awards are restricted stock units that convert into one share each and vest one month after grant, and that the Q1 2026 RSUs were filed late due to an administrative error.
Corvese Brian reported acquisition or exercise transactions in this Form 4 filing.
MiNK Therapeutics director Brian Corvese received stock-based board compensation rather than cash. He was granted 1,444 restricted stock units (RSUs) at $12.38 and 1,640 RSUs at $10.90 as compensation for board and committee retainers. The RSUs vest one month from each grant, and his direct common stock holdings total 53,137 shares after these awards. RSUs for Q1 2026 board and committee compensation were reported late due to an administrative error.
Behner Peter reported acquisition or exercise transactions in this Form 4 filing.
MiNK Therapeutics, Inc. director Peter Behner reported stock-based board compensation. He received 1,313 restricted stock units on June 1, 2026 and 1,491 units on March 2, 2026, each convertible into common shares and granted in lieu of cash retainers. The RSUs vest one month after each grant, bringing his direct holdings to 22,919 common shares.
The company noted that the RSUs for Q1 2026 board and committee compensation were not filed on time due to an administrative error.
WIINBERG ULF reported acquisition or exercise transactions in this Form 4 filing.
MiNK Therapeutics director Ulf Wiinberg reported stock-based board compensation rather than open-market trading. On June 1, 2026, he received 1,131 shares of Common Stock at $12.38 per share as a grant in lieu of cash retainers, bringing his direct holdings to 22,650 shares.
The filing also shows a prior grant of 1,285 shares on March 2, 2026 at $10.90 per share, with 21,519 shares held directly after that award. In addition, 27,830 shares are held indirectly in an irrevocable trust for the benefit of his family. Footnotes state these restricted stock units vest one month after grant and that the Q1 2026 grant was filed late due to an administrative error.
MiNK Therapeutics, Inc. reported a net loss of $2.7 million for the three months ended March 31, 2026, similar to the prior-year period. Research and development expense was $1.2 million while general and administrative expense rose to $1.7 million, mainly from higher share-based compensation and professional fees.
Cash and cash equivalents were $9.5 million as of March 31, 2026, and the company has an accumulated deficit of $159.4 million. It raised about $3.0 million via at-the-market stock sales in the quarter and an additional $150,000 afterward, and repaid a $5.0 million related-party convertible note in January 2026. Management states that while existing cash plus anticipated funding are expected to cover more than one year of liquidity needs, completion of funding is not fully within its control, so substantial doubt exists about its ability to continue as a going concern.